Pacific Edge (ASX:PEB, NZE:PEB) said the draft 'Gapfill' prices for Cxbladder Triage Plus, a non-invasive genomic urine test, published by the US Centers for Medicare & Medicaid Services, proposed a draft price for the test of $1,018.44, according to Tuesday's Australian and New Zealand bourse filings.
The draft price sets the amount Pacific Edge will be reimbursed for all patients with Medicare and Medicare Advantage insurance in the US, subject to the Medicare Administrative Contractor, Novitas, providing coverage of the test.
It is currently listed as non-covered on Novitas' local coverage determination. The price is expected to take effect on Jan. 1, 2026.
Pacific Edge expects to submit a reconsideration request for coverage of Triage Plus as soon as the analytical validation and clinical validation studies have been published, per the filing.
Its shares soared 10% on market close on the New Zealand bourse.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。